Veracyte shares jump 19.96% intraday after Q3 revenue and EPS beat estimates, guidance raised, and analyst price targets increased by Needham and Canaccord.

Veracyte (NASDAQ:VCYT) surged 19.96% intraday following the release of its third-quarter 2025 earnings report, which showed revenue growth of 14% to $131.9 million and a 30% adjusted EBITDA margin, surpassing analyst expectations. The results prompted multiple analyst upgrades, including a $44 price target from Needham and a $43 target from Canaccord Genuity, reflecting confidence in the company’s strong performance in Decipher Prostate and Afirma testing segments. Veracyte also raised its 2025 revenue and EBITDA margin guidance, driven by improved operational efficiency and new product initiatives such as minimal residual disease tests. The stock’s sharp rise aligned with positive sentiment around its financial health, including a debt-free balance sheet and robust cash reserves, as well as optimism about long-term growth in genomic diagnostics.